|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SUPT6H |
Gene summary for SUPT6H |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SUPT6H | Gene ID | 6830 |
| Gene name | SPT6 homolog, histone chaperone and transcription elongation factor | |
| Gene Alias | SPT6 | |
| Cytomap | 17q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0000018 | UniProtAcc | Q7KZ85 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6830 | SUPT6H | LZE2T | Human | Esophagus | ESCC | 8.79e-03 | 4.97e-01 | 0.082 |
| 6830 | SUPT6H | LZE4T | Human | Esophagus | ESCC | 1.33e-14 | 5.34e-01 | 0.0811 |
| 6830 | SUPT6H | LZE7T | Human | Esophagus | ESCC | 1.37e-08 | 4.81e-01 | 0.0667 |
| 6830 | SUPT6H | LZE8T | Human | Esophagus | ESCC | 4.07e-08 | 3.14e-01 | 0.067 |
| 6830 | SUPT6H | LZE20T | Human | Esophagus | ESCC | 1.88e-10 | 1.91e-01 | 0.0662 |
| 6830 | SUPT6H | LZE22T | Human | Esophagus | ESCC | 3.39e-08 | 3.30e-01 | 0.068 |
| 6830 | SUPT6H | LZE24T | Human | Esophagus | ESCC | 2.17e-17 | 6.07e-01 | 0.0596 |
| 6830 | SUPT6H | LZE21T | Human | Esophagus | ESCC | 4.13e-03 | 5.81e-01 | 0.0655 |
| 6830 | SUPT6H | P1T-E | Human | Esophagus | ESCC | 3.03e-20 | 8.67e-01 | 0.0875 |
| 6830 | SUPT6H | P2T-E | Human | Esophagus | ESCC | 1.24e-21 | 6.03e-01 | 0.1177 |
| 6830 | SUPT6H | P4T-E | Human | Esophagus | ESCC | 2.44e-20 | 4.59e-01 | 0.1323 |
| 6830 | SUPT6H | P5T-E | Human | Esophagus | ESCC | 6.27e-08 | 2.35e-01 | 0.1327 |
| 6830 | SUPT6H | P8T-E | Human | Esophagus | ESCC | 1.64e-28 | 6.19e-01 | 0.0889 |
| 6830 | SUPT6H | P9T-E | Human | Esophagus | ESCC | 9.99e-16 | 3.41e-01 | 0.1131 |
| 6830 | SUPT6H | P10T-E | Human | Esophagus | ESCC | 5.42e-27 | 6.58e-01 | 0.116 |
| 6830 | SUPT6H | P11T-E | Human | Esophagus | ESCC | 1.35e-14 | 6.47e-01 | 0.1426 |
| 6830 | SUPT6H | P12T-E | Human | Esophagus | ESCC | 2.08e-23 | 4.97e-01 | 0.1122 |
| 6830 | SUPT6H | P15T-E | Human | Esophagus | ESCC | 2.08e-28 | 6.94e-01 | 0.1149 |
| 6830 | SUPT6H | P16T-E | Human | Esophagus | ESCC | 3.84e-19 | 3.65e-01 | 0.1153 |
| 6830 | SUPT6H | P17T-E | Human | Esophagus | ESCC | 4.73e-09 | 3.99e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001593131 | Oral cavity | NEOLP | nucleobase-containing compound transport | 48/2005 | 222/18723 | 1.51e-06 | 3.77e-05 | 48 |
| GO:004269221 | Oral cavity | NEOLP | muscle cell differentiation | 71/2005 | 384/18723 | 2.97e-06 | 6.76e-05 | 71 |
| GO:004683131 | Oral cavity | NEOLP | regulation of RNA export from nucleus | 8/2005 | 12/18723 | 5.68e-06 | 1.16e-04 | 8 |
| GO:005102831 | Oral cavity | NEOLP | mRNA transport | 31/2005 | 130/18723 | 1.38e-05 | 2.43e-04 | 31 |
| GO:003105631 | Oral cavity | NEOLP | regulation of histone modification | 34/2005 | 152/18723 | 2.31e-05 | 3.72e-04 | 34 |
| GO:000632521 | Oral cavity | NEOLP | chromatin organization | 70/2005 | 409/18723 | 4.97e-05 | 6.83e-04 | 70 |
| GO:005105231 | Oral cavity | NEOLP | regulation of DNA metabolic process | 63/2005 | 359/18723 | 5.48e-05 | 7.44e-04 | 63 |
| GO:00322392 | Oral cavity | NEOLP | regulation of nucleobase-containing compound transport | 8/2005 | 15/18723 | 5.49e-05 | 7.44e-04 | 8 |
| GO:000647922 | Oral cavity | NEOLP | protein methylation | 37/2005 | 181/18723 | 8.15e-05 | 1.02e-03 | 37 |
| GO:000821322 | Oral cavity | NEOLP | protein alkylation | 37/2005 | 181/18723 | 8.15e-05 | 1.02e-03 | 37 |
| GO:001820531 | Oral cavity | NEOLP | peptidyl-lysine modification | 64/2005 | 376/18723 | 1.21e-04 | 1.43e-03 | 64 |
| GO:003296821 | Oral cavity | NEOLP | positive regulation of transcription elongation from RNA polymerase II promoter | 7/2005 | 13/18723 | 1.53e-04 | 1.74e-03 | 7 |
| GO:001657122 | Oral cavity | NEOLP | histone methylation | 30/2005 | 141/18723 | 1.77e-04 | 1.95e-03 | 30 |
| GO:003496822 | Oral cavity | NEOLP | histone lysine methylation | 25/2005 | 115/18723 | 4.21e-04 | 3.89e-03 | 25 |
| GO:003106021 | Oral cavity | NEOLP | regulation of histone methylation | 17/2005 | 69/18723 | 7.76e-04 | 6.23e-03 | 17 |
| GO:000640531 | Oral cavity | NEOLP | RNA export from nucleus | 19/2005 | 84/18723 | 1.20e-03 | 8.85e-03 | 19 |
| GO:00342433 | Oral cavity | NEOLP | regulation of transcription elongation from RNA polymerase II promoter | 10/2005 | 32/18723 | 1.36e-03 | 9.75e-03 | 10 |
| GO:00714263 | Oral cavity | NEOLP | ribonucleoprotein complex export from nucleus | 17/2005 | 76/18723 | 2.41e-03 | 1.54e-02 | 17 |
| GO:00310572 | Oral cavity | NEOLP | negative regulation of histone modification | 12/2005 | 46/18723 | 2.66e-03 | 1.66e-02 | 12 |
| GO:00711663 | Oral cavity | NEOLP | ribonucleoprotein complex localization | 17/2005 | 77/18723 | 2.80e-03 | 1.73e-02 | 17 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SUPT6H | SNV | Missense_Mutation | c.388N>T | p.Asp130Tyr | p.D130Y | Q7KZ85 | protein_coding | deleterious(0) | possibly_damaging(0.791) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| SUPT6H | SNV | Missense_Mutation | c.5009N>G | p.Ala1670Gly | p.A1670G | Q7KZ85 | protein_coding | tolerated(0.37) | benign(0.066) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| SUPT6H | SNV | Missense_Mutation | rs755836482 | c.4562N>C | p.Gly1521Ala | p.G1521A | Q7KZ85 | protein_coding | tolerated(0.12) | possibly_damaging(0.505) | TCGA-A8-A08B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| SUPT6H | SNV | Missense_Mutation | c.3218N>T | p.Ala1073Val | p.A1073V | Q7KZ85 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SUPT6H | SNV | Missense_Mutation | c.3817N>C | p.Glu1273Gln | p.E1273Q | Q7KZ85 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SUPT6H | SNV | Missense_Mutation | c.295G>A | p.Asp99Asn | p.D99N | Q7KZ85 | protein_coding | deleterious(0.01) | probably_damaging(0.956) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| SUPT6H | SNV | Missense_Mutation | c.298N>A | p.Asp100Asn | p.D100N | Q7KZ85 | protein_coding | deleterious(0.02) | probably_damaging(0.956) | TCGA-C8-A131-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| SUPT6H | SNV | Missense_Mutation | c.3779G>C | p.Gly1260Ala | p.G1260A | Q7KZ85 | protein_coding | deleterious(0.02) | possibly_damaging(0.705) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| SUPT6H | SNV | Missense_Mutation | c.22N>A | p.Glu8Lys | p.E8K | Q7KZ85 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.905) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SUPT6H | SNV | Missense_Mutation | c.388G>T | p.Asp130Tyr | p.D130Y | Q7KZ85 | protein_coding | deleterious(0) | possibly_damaging(0.791) | TCGA-D8-A1X7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | ChemotherapyHormone Therapy | doxorubicine+cyclophosphamide+tamoxifen | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |